{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T10:58:24Z","timestamp":1788260304993,"version":"build-2803163510"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,4,7]],"date-time":"2023-04-07T00:00:00Z","timestamp":1680825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004366","name":"Tabriz University of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004366","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Oxidative stress is considered a major factor in the pathophysiology of non-alcoholic liver disease (NAFLD). A growing body of evidence indicates that oleoylethanolamide (OEA), a bioactive lipid mediator, has anti-inflammatory and antioxidant properties. This trial investigated the effects of OEA administration on inflammatory markers, oxidative stress and antioxidant parameters of patients with NAFLD.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> The present randomized controlled trial was conducted on 60 obese patients with NAFLD. The patients were treated with OEA (250\u00a0mg\/day) or placebo along with a low-calorie diet for 12\u2009weeks. Inflammatory markers and oxidative stress and antioxidant parameters were evaluated pre-and post-intervention.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> At the end of the study, neither the between-group changes, nor the within-group differences were significant for serum levels of high-sensitivity C-reactive protein (hs-CRP), interleukin-1 beta (IL-1\u03b2), IL-6, IL-10, and tumor necrosis-factor \u03b1 (TNF-\u03b1). Serum levels of total antioxidant capacity (TAC) and superoxide dismutase (SOD) significantly increased and serum concentrations of malondialdehyde (MDA) and oxidized-low density lipoprotein (ox-LDL) significantly decreased in the OEA group compared to placebo at study endpoint (<jats:italic>p<\/jats:italic> = 0.039, 0.018, 0.003 and 0.001, respectively). Although, no significant between-group alterations were found in glutathione peroxidase and catalase. There were significant correlations between percent of changes in serum oxidative stress and antioxidant parameters with percent of changes in some anthropometric indices in the intervention group.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> OEA supplementation could improve some oxidative stress\/antioxidant biomarkers without any significant effect on inflammation in NAFLD patients. Further clinical trials with longer follow-up periods are demanded to verify profitable effects of OEA in these patients.<\/jats:p><jats:p><jats:bold>Clinical Trial Registration:<\/jats:bold><jats:ext-link>www.irct.ir<\/jats:ext-link>, Iranian Registry of Clinical Trials IRCT20090609002017N32.<\/jats:p>","DOI":"10.3389\/fphar.2023.1144550","type":"journal-article","created":{"date-parts":[[2023,4,7]],"date-time":"2023-04-07T04:22:49Z","timestamp":1680841369000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":23,"title":["Effects of oleoylethanolamide supplementation on inflammatory biomarkers, oxidative stress and antioxidant parameters of obese patients with NAFLD on a calorie-restricted diet: A randomized controlled trial"],"prefix":"10.3389","volume":"14","author":[{"given":"Helda","family":"Tutunchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farideh","family":"Zolrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahlagha","family":"Nikbaf-Shandiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Naeini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Ostadrahimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sina","family":"Naghshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Salek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farzad","family":"Najafipour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,4,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"846","DOI":"10.4254\/wjh.v7.i6.846","article-title":"Non-alcoholic fatty liver disease: The diagnosis and management","volume":"7","author":"Abd El-Kader","year":"2015","journal-title":"World J. Hepatol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"126945","DOI":"10.1016\/j.jtemb.2022.126945","article-title":"Possible therapeutic effects of boron citrate and oleoylethanolamide supplementation in patients with COVID-19: A pilot randomized, double-blind, clinical trial","volume":"71","author":"Akbari","year":"2022","journal-title":"J. trace Elem. Med. Biol. organ Soc. Minerals Trace Elem. (GMS)"},{"key":"B3","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1111\/adb.12365","article-title":"Oleoylethanolamide prevents neuroimmune HMGB1\/TLR4\/NF-kB danger signaling in rat frontal cortex and depressive-like behavior induced by ethanol binge administration","volume":"22","author":"Ant\u00f3n","year":"2017","journal-title":"Addict. Biol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"715","DOI":"10.4254\/wjh.v9.i16.715","article-title":"Non-alcoholic fatty liver disease: An expanded review","volume":"9","author":"Benedict","year":"2017","journal-title":"World J. Hepatol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"727","DOI":"10.3748\/wjg.v18.i8.727","article-title":"Role of cytokines and chemokines in non-alcoholic fatty liver disease","volume":"18","author":"Braunersreuther","year":"2012","journal-title":"World J. gastroenterology"},{"key":"B6","doi-asserted-by":"publisher","first-page":"42530","DOI":"10.18632\/oncotarget.6466","article-title":"Oleoylethanolamide, an endogenous PPAR-\u03b1 ligand, attenuates liver fibrosis targeting hepatic stellate cells","volume":"6","author":"Chen","year":"2015","journal-title":"Oncotarget"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1249\/01.MSS.0000078924.61453.FB","article-title":"International physical activity questionnaire: 12-country reliability and validity","volume":"35","author":"Craig","year":"2003","journal-title":"Med. Sci. sports Exerc."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1038\/s41467-022-30338-z","article-title":"Identification of oleoylethanolamide as an endogenous ligand for HIF-3\u03b1","volume":"13","author":"Diao","year":"2022","journal-title":"Nat. Commun."},{"key":"B9","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1111\/apt.15673","article-title":"Modelling NAFLD disease burden in four Asian regions-2019-2030","volume":"51","author":"Estes","year":"2020","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B10","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1002\/hep.29466","article-title":"Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease","volume":"67","author":"Estes","year":"2018","journal-title":"Hepatol. Baltim. Md)"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e85337","DOI":"10.1371\/journal.pone.0085337","article-title":"Atheroprotective effect of oleoylethanolamide (OEA) targeting oxidized LDL","volume":"9","author":"Fan","year":"2014","journal-title":"PLoS One"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.3390\/cells9071638","article-title":"Peroxisome proliferator-activated receptors and their novel ligands as candidates for the treatment of non-alcoholic fatty liver disease","volume":"9","author":"Fougerat","year":"2020","journal-title":"Cells"},{"key":"B13","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/nature01921","article-title":"Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha","volume":"425","author":"Fu","year":"2003","journal-title":"Nature"},{"key":"B14","doi-asserted-by":"publisher","first-page":"R45","DOI":"10.1152\/ajpregu.00126.2008","article-title":"Targeted enhancement of oleoylethanolamide production in proximal small intestine induces across-meal satiety in rats","volume":"295","author":"Fu","year":"2008","journal-title":"Am. J. physiology Regul. Integr. Comp. physiology"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.3390\/antiox10081289","article-title":"Oleoylethanolamide reduces hepatic oxidative stress and endoplasmic reticulum stress in high-fat diet-fed rats","volume":"10","author":"Giudetti","year":"2021","journal-title":"Antioxidants (Basel, Switz."},{"key":"B16","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/nrendo.2016.135","article-title":"PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD","volume":"13","author":"Gross","year":"2017","journal-title":"Nat. Rev. Endocrinol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"27849","DOI":"10.1074\/jbc.M404087200","article-title":"Oleoylethanolamide stimulates lipolysis by activating the nuclear receptor peroxisome proliferator-activated receptor alpha (PPAR-alpha)","volume":"279","author":"Guzm\u00e1n","year":"2004","journal-title":"J. Biol. Chem."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2708","DOI":"10.1111\/j.1572-0241.2007.01526.x","article-title":"The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation","volume":"102","author":"Hamaguchi","year":"2007","journal-title":"Am. J. Gastroenterol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"605065","DOI":"10.3389\/fphar.2020.605065","article-title":"Oleoylethanolamide protects against acute liver injury by regulating nrf-2\/HO-1 and NLRP3 pathways in mice","volume":"11","author":"Hu","year":"2020","journal-title":"Front. Pharmacol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1002\/hep.28289","article-title":"Inhibition of hedgehog signaling ameliorates hepatic inflammation in mice with nonalcoholic fatty liver disease","volume":"63","author":"Kwon","year":"2016","journal-title":"Hepatol. Baltim. Md)"},{"key":"B21","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.appet.2018.05.129","article-title":"Oleoylethanolamide increases the expression of PPAR-\u0391 and reduces appetite and body weight in obese people: A clinical trial","volume":"128","author":"Laleh","year":"2018","journal-title":"Appetite"},{"key":"B22","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.jphs.2014.12.001","article-title":"Effect of oleoylethanolamide on diet-induced nonalcoholic fatty liver in rats","volume":"127","author":"Li","year":"2015","journal-title":"J. Pharmacol. Sci."},{"key":"B23","doi-asserted-by":"publisher","first-page":"26087","DOI":"10.3390\/ijms161125942","article-title":"The role of oxidative stress and antioxidants in liver diseases","volume":"16","author":"Li","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"B24","first-page":"6301","article-title":"Inhibitory effects of oleoylethanolamide (OEA) on H-O-induced human umbilical vein endothelial cell (HUVEC) injury and apolipoprotein E knockout (ApoE-\/-) atherosclerotic mice","volume":"8","author":"Ma","year":"2015","journal-title":"Int. J. Clin. Exp. pathology"},{"key":"B25","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3390\/antiox11010091","article-title":"Oxidative stress is a key modulator in the development of nonalcoholic fatty liver disease","volume":"11","author":"Ma","year":"2021","journal-title":"Antioxidants (Basel, Switz."},{"key":"B26","doi-asserted-by":"publisher","first-page":"101049","DOI":"10.1016\/j.molmet.2020.101049","article-title":"Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis","volume":"50","author":"Mahjoubin-Tehran","year":"2021","journal-title":"Mol. Metab."},{"key":"B27","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1089\/met.2015.0095","article-title":"Obesity, oxidative stress, adipose tissue dysfunction, and the associated health risks: Causes and therapeutic strategies","volume":"13","author":"Manna","year":"2015","journal-title":"Metab. Syndr. Relat. Disord."},{"key":"B28","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.cmet.2018.09.014","article-title":"Mast cell-derived histamine regulates liver ketogenesis via oleoylethanolamide signaling","volume":"29","author":"Misto","year":"2019","journal-title":"Cell Metab."},{"key":"B29","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.phrs.2003.12.006","article-title":"Oleoylethanolamide inhibits food intake in free-feeding rats after oral administration","volume":"49","author":"Oveisi","year":"2004","journal-title":"Pharmacol. Res."},{"key":"B30","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.immuni.2014.09.008","article-title":"HIF transcription factors, inflammation, and immunity","volume":"41","author":"Palazon","year":"2014","journal-title":"Immunity"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1194\/jlr.M089250","article-title":"Oleoylethanolamide differentially regulates glycerolipid synthesis and lipoprotein secretion in intestine and liver","volume":"59","author":"Pan","year":"2018","journal-title":"J. lipid Res."},{"key":"B32","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s10238-015-0347-4","article-title":"Severity of non-alcoholic fatty liver disease is associated with high systemic levels of tumor necrosis factor alpha and low serum interleukin 10 in morbidly obese patients","volume":"16","author":"Paredes-Turrubiarte","year":"2016","journal-title":"Clin. Exp. Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"479","DOI":"10.15171\/apb.2018.056","article-title":"Oleoylethanolamide supplementation reduces inflammation and oxidative stress in obese people: A clinical trial","volume":"8","author":"Payahoo","year":"2018","journal-title":"Adv. Pharm. Bull."},{"key":"B34","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.freeradbiomed.2011.10.003","article-title":"Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis","volume":"52","author":"Rolo","year":"2012","journal-title":"Free Radic. Biol. Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"5721167","DOI":"10.1155\/2022\/5721167","article-title":"The effect of oleoylethanolamide (OEA) add-on treatment on inflammatory, oxidative stress, lipid, and biochemical parameters in the acute ischemic stroke patients: Randomized double-blind placebo-controlled study","volume":"2022","author":"Sabahi","year":"2022","journal-title":"Oxid. Med. Cell Longev."},{"key":"B36","doi-asserted-by":"publisher","first-page":"pyu111","DOI":"10.1093\/ijnp\/pyu111","article-title":"Systemic administration of oleoylethanolamide protects from neuroinflammation and anhedonia induced by LPS in rats","volume":"18","author":"Sayd","year":"2014","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"931","DOI":"10.14218\/JCTH.2021.00174","article-title":"Nonalcoholic fatty liver disease (NAFLD) name change: Requiem or reveille?","volume":"9","author":"Singh","year":"2021","journal-title":"J. Clin. Transl. hepatology"},{"key":"B38","doi-asserted-by":"publisher","first-page":"18070","DOI":"10.3748\/wjg.v20.i48.18070","article-title":"Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease","volume":"20","author":"Stojsavljevi\u0107","year":"2014","journal-title":"World J. gastroenterology"},{"key":"B39","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1038\/sj.bjp.0707478","article-title":"Cannabinoid activation of PPAR alpha; a novel neuroprotective mechanism","volume":"152","author":"Sun","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"20704","DOI":"10.3390\/ijms141020704","article-title":"Multiple hits, including oxidative stress, as pathogenesis and treatment target in non-alcoholic steatohepatitis (NASH)","volume":"14","author":"Takaki","year":"2013","journal-title":"Int. J. Mol. Sci."},{"key":"B41","doi-asserted-by":"publisher","first-page":"373","DOI":"10.34172\/hpp.2020.56","article-title":"Effects of oleoylethanolamide supplementation on atherogenic indices and hematological parameters in patients with nonalcoholic fatty liver disease: A clinical trial","volume":"10","author":"Tutunchi","year":"2020","journal-title":"Health Promot Perspect."},{"key":"B42","doi-asserted-by":"publisher","first-page":"104770","DOI":"10.1016\/j.phrs.2020.104770","article-title":"Oleoylethanolamide supplementation in obese patients newly diagnosed with non-alcoholic fatty liver disease: Effects on metabolic parameters, anthropometric indices, and expression of PPAR-\u03b1, UCP1, and UCP2 genes","volume":"156","author":"Tutunchi","year":"2020","journal-title":"Pharmacol. Res."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1111\/obr.12853","article-title":"The effects of oleoylethanolamide, an endogenous PPAR-\u03b1 agonist, on risk factors for NAFLD: A systematic review","volume":"20","author":"Tutunchi","year":"2019","journal-title":"Obes. Rev. official J. Int. Assoc. Study Obes."},{"key":"B44","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1002\/jcp.29870","article-title":"Expression of NF-\u03baB, IL-6, and IL-10 genes, body composition, and hepatic fibrosis in obese patients with NAFLD-combined effects of oleoylethanolamide supplementation and calorie restriction: A triple-blind randomized controlled clinical trial","volume":"236","author":"Tutunchi","year":"2021","journal-title":"J. Cell Physiol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/s13104-020-05059-5","article-title":"The relationship between severity of liver steatosis and metabolic parameters in a sample of Iranian adults","volume":"13","author":"Tutunchi","year":"2020","journal-title":"BMC Res. Notes"},{"key":"B46","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41423-020-00579-3","article-title":"Immunological mechanisms and therapeutic targets of fatty liver diseases","volume":"18","author":"Wang","year":"2021","journal-title":"Cell Mol. Immunol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"34611","DOI":"10.1038\/srep34611","article-title":"Oleoylethanolamide exerts anti-inflammatory effects on LPS-induced THP-1 cells by enhancing PPAR\u03b1 signaling and inhibiting the NF-\u03baB and ERK1\/2\/AP-1\/STAT3 pathways","volume":"6","author":"Yang","year":"2016","journal-title":"Sci. Rep."},{"key":"B48","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1002\/biof.5520330306","article-title":"Effect of acylethanolamides on lipid peroxidation and paraoxonase activity","volume":"33","author":"Zolese","year":"2008","journal-title":"BioFactors Oxf. Engl."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1144550\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,7]],"date-time":"2023-04-07T04:22:52Z","timestamp":1680841372000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1144550\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,7]]},"references-count":48,"alternative-id":["10.3389\/fphar.2023.1144550"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1144550","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,7]]},"article-number":"1144550"}}